Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001549595-25-000055
Filing Date
2025-04-08
Accepted
2025-04-08 16:06:50
Documents
66
Period of Report
2025-02-28

Document Format Files

Seq Description Document Type Size
1 10-Q nrix-20250228.htm   iXBRL 10-Q 1381219
2 EX-10.1 a1600sierrapointparkwaysub.htm EX-10.1 169356
3 EX-31.1 nrix-20250228x10qxex311.htm EX-31.1 10852
4 EX-31.2 nrix-20250228x10qxex312.htm EX-31.2 10842
5 EX-32.1 nrix-20250228x10qxex321.htm EX-32.1 8427
  Complete submission text file 0001549595-25-000055.txt   6349066

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nrix-20250228.xsd EX-101.SCH 40068
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT nrix-20250228_cal.xml EX-101.CAL 51479
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nrix-20250228_def.xml EX-101.DEF 202114
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nrix-20250228_lab.xml EX-101.LAB 570684
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nrix-20250228_pre.xml EX-101.PRE 381374
69 EXTRACTED XBRL INSTANCE DOCUMENT nrix-20250228_htm.xml XML 648698
Mailing Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158
Business Address 1700 OWENS STREET, SUITE 205 SAN FRANCISCO CA 94158 (415) 660-5320
Nurix Therapeutics, Inc. (Filer) CIK: 0001549595 (see all company filings)

EIN.: 270838048 | State of Incorp.: DE | Fiscal Year End: 1130
Type: 10-Q | Act: 34 | File No.: 001-39398 | Film No.: 25821986
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)